^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gallbladder Cancer

    Related cancers:
    2d
    Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, University of Nebraska | Trial primary completion date: Oct 2025 --> May 2026
    Trial primary completion date
    3d
    A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2024 --> May 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • Koselugo (selumetinib)
    3d
    KEYNOTE-D86: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Genome & Company | Recruiting --> Terminated | N=148 --> 10; Sponsor decision
    Enrollment change • Trial termination
    |
    Keytruda (pembrolizumab) • GEN-001
    4d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Yale University
    New P2 trial • Circulating tumor DNA
    4d
    Precision Targeted-Immunotherapy for BRAF V600E and MET-Amplified Biliary Tract Cancer: Two Case Reports. (PubMed, Oncologist)
    Combining targeted therapies with immune checkpoint inhibitors showed promising results in two patients with advanced BTC driven by specific genetic mutations. Significant tumor reduction and successful surgeries suggest this approach may improve resectability and outcomes. These cases highlight the potential of personalized treatment guided by genetic profiling. Further research is needed to confirm these findings and explore broader applications for this strategy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • MET amplification
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Imfinzi (durvalumab) • Tepmetko (tepotinib)
    5d
    LAMC2 promotes gallbladder carcinoma metastasis through the TGF-β pathway. (PubMed, Cancer Cell Int)
    Our findings suggest that LAMC2 promotes GBC progression and metastasis, potentially by regulating the TGF-β signaling pathway. Therefore, LAMC2 could serve as a potential prognostic biomarker and therapeutic target for GBC.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • LAMC2 (Laminin subunit gamma 2)
    7d
    Biliary concentration of CA19-9 and CA125, iron metabolism markers, and PIVKA-II activity in pancreatobiliary tumors. (PubMed, Dig Dis)
    CA125 and hepcidin as quantitative markers, along with PIVKA-II as a qualitative marker, demonstrate significant potential as biliary markers for distinguishing choledocholithiasis from biliary tract or pancreatic cancers. Biliary iron, TIBC, and CA19-9 require further investigation to confirm their diagnostic yield.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    9d
    Primary extra-gastrointestinal stromal tumor of the gallbladder: A case report. (PubMed, World J Gastroenterol)
    Primary gallbladder EGISTs are exceedingly rare, with insidious onset and nonspecific clinical manifestations. Histopathological examination combined with immunohistochemistry remains the cornerstone of definitive diagnosis.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • ANO1 (Anoctamin 1)
    |
    imatinib
    9d
    Loss of Branched-Chain Amino Acid (BCAA) Metabolism Mediated by IGF2BP1-LPAL2-YBX1 Interaction Promotes Malignancy in Gallbladder Cancer. (PubMed, Cancer Lett)
    Additionally, LPAL2 decreased YBX1 stability by promoting its ubiquitination-mediated degradation, while YBX1 inhibited the transcription of certain BCAA catabolic enzymes through binding to their promoters. In summary, the LPAL2-YBX1 interaction regulates BCAA metabolism to influence GBC cell proliferation, which could be targeted for therapeutic interventions in GBC treatment.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • YBX1 (Y-Box Binding Protein 1) • ACADSB (Acyl-CoA Dehydrogenase Short/Branched Chain)
    14d
    Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, University of Southern California | Trial completion date: Dec 2025 --> Jul 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • guadecitabine (SGI-110)